Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2025 | Story Reuben Maeko | Photo Sizwe Gwiba
Dermatology Unit
Celebrating the milestone launch of the Dermatologic Surgery Unit at Universitas Academic Hospital, a new chapter for advanced patient care, training, and research.

The Department of Dermatology in the Faculty of Health Sciences at the University of the Free State (UFS) marked a historic milestone with the official opening of the Dermatologic Surgery Unit at Universitas Academic Hospital on 11 September 2025. This new facility represents a significant step forward in expanding access to specialised surgical treatment for complex dermatological conditions, while simultaneously strengthening academic training and research opportunities for registrars and medical students.

The inauguration was attended by Prof Francois P Retief, a distinguished medical pioneer from the UFS Faculty of Health Sciences, after whom one of the faculty buildings is named. His wife, Ria Retief, extended words of gratitude and gifted a book from his medical library to Prof Frans Maruma, Head of the Department of Dermatology.

“We are truly honoured to be included in this significant milestone and to witness the beginning of what we know will be an impactful journey aimed at improving patient care,” Ria Retief said. “It is a privilege to celebrate this remarkable achievement with you, and we deeply admire your dedication and vision.”

 

Honouring a legacy in dermatology

In his opening address, Prof Maruma reflected on the journey that led to the establishment of the Dermatologic Surgery Unit, acknowledging the teamwork, persistence, and collaboration that made the vision a reality.

“The Derm-Surgery Unit is not just a surgical space – it is a testament to teamwork, perseverance, and the drive to advance patient-centred care in dermatology,” he said. “We pay homage to visionary leadership that has afforded us the opportunity to expand dermatology services to include surgery and as a skill sacrosanct to modern practice. This is not only about healing, but also about preparing our registrars for the realities of clinical practice through work-integrated learning.”

Prof Maruma extended appreciation to colleagues and staff members in the Department of Dermatology, as well as strategic partners in the UFS, the Department of Health, the pharmaceutical industry, and private practitioners who dedicate their time to teaching and mentoring. Special acknowledgement was given to Dr Marc Roscher, Dr Harriet Makuru, and Dr Yashica Khalawan, who played a pivotal role in supporting the project’s launch.

The programme also included remarks by senior academic leaders. Prof Alicia Sherriff, Acting Head of the School of Clinical Medicine, commended the department for its innovation and foresight in the face of resource limitations, highlighting the potential for further expansion through collaboration with both public and private stakeholders.

While cutting the ribbon, Prof Thabiso Mofokeng, Head of Internal Medicine at Universitas Academic Hospital, emphasised that the launch of the Derm-Surgery Unit reflects the broader ethos of the clinical platform: to enable world-class training, foster research excellence, and deliver quality healthcare that is responsive to the needs of the community.

The launch underscored the university’s commitment to Work-Integrated Learning (WIL), bridging the gap between academic training and real-world clinical demands. The Derm-Surgery initiative is designed to equip registrars with essential industry-specific skills in procedural dermatology while fostering collaboration between private and public healthcare sectors. The evening concluded with awards recognising individuals whose contributions ensured the success of this landmark opening.

Looking ahead, the Department of Dermatology envisions its Derm-Surgery Unit as more than just a clinical unit – it is set to become a hub of advanced patient care, high-impact training, and cutting-edge research. This initiative strengthens the UFS Faculty of Health Sciences’ role as a leader in medical education and healthcare innovation in the Free State and beyond.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept